Amphastar Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $0.77 | $0.77 | $0.77 |
| Q2 2024 | 3 | $0.77 | $0.77 | $0.77 |
| Q3 2024 | 5 | $0.89 | $1.11 | $1.01 |
| Q4 2024 | 3 | $0.99 | $0.99 | $0.99 |
| Q1 2025 | 4 | $1.01 | $1.01 | $1.01 |
| Q2 2025 | 4 | $1.07 | $1.07 | $1.07 |
| Q3 2025 | 4 | $1.20 | $1.20 | $1.20 |
| Q4 2025 | 4 | $1.27 | $1.27 | $1.27 |
Amphastar Pharmaceuticals, Inc. Earnings Date And Information
Amphastar Pharmaceuticals, Inc. last posted its earnings results on Wednesday, August 7th, 2024. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.77 by $0.17. The company had revenue of 182.39 M for the quarter and had revenue of 644.40 M for the year. Amphastar Pharmaceuticals, Inc. has generated $3 earnings per share over the last year ($2.6 diluted earnings per share) and currently has a price-to-earnings ratio of 15.02. Amphastar Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based on prior year's report dates.
Amphastar Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/09/2024 | Q2 2024 | $0.78 | $170.96 M | $182.39 M | ||
| 05/09/2024 | Q1 2024 | $0.90 | $171.84 M | |||
| 02/29/2024 | Q4 2023 | $0.75 | $178.11 M | |||
| 11/08/2023 | Q3 2023 | $0.69 | $1.01 | 0.32 | $174.63 M | $180.56 M |
| 08/08/2023 | Q2 2023 | $0.54 | $137.27 M | $145.71 M | ||
| 05/09/2023 | Q1 2023 | $0.48 | $0.54 | 0.06 | $140.02 M | |
| 03/01/2023 | Q4 2022 | $0.70 | $135.02 M | |||
| 11/07/2022 | Q3 2022 | $0.30 | $125.98 M | $120.13 M | ||
| 08/08/2022 | Q2 2022 | $0.35 | $118.08 M | $123.47 M | ||
| 05/09/2022 | Q1 2022 | $0.47 | $120.37 M | |||
| 03/11/2022 | Q4 2021 | $0.41 | $120.89 M | |||
| 11/08/2021 | Q3 2021 | $0.62 | $103.25 M | $112.20 M | ||
| 08/09/2021 | Q2 2021 | $0.21 | $0.16 | -0.05 | $101.30 M | $101.66 M |
| 05/07/2021 | Q1 2021 | $0.11 | $103.02 M | |||
| 03/15/2021 | Q4 2020 | $0.14 | -$0.13 | -0.27 | $95.92 M | |
| 11/06/2020 | Q3 2020 | $0.13 | $0.08 | -0.05 | $91.23 M | $83.43 M |
| 08/07/2020 | Q2 2020 | -$0.00 | $86.73 M | $85.81 M | ||
| 05/11/2020 | Q1 2020 | $0.09 | $84.69 M | |||
| 03/16/2020 | Q4 2019 | -$0.02 | $83.38 M | |||
| 11/08/2019 | Q3 2019 | $0.03 | $78.57 M | $80.14 M |
Amphastar Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Amphastar Pharmaceuticals, Inc.'s earnings date?
Amphastar Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 6th, 2024 based off last year's report dates.
-
Did Amphastar Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Amphastar Pharmaceuticals, Inc. (:AMPH) reported $0.94 earnings per share (EPS) to beat the analysts' consensus estimate of $0.77 by $0.17.
-
How can I listen to Amphastar Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Amphastar Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Amphastar Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Amphastar Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Amphastar Pharmaceuticals, Inc. generate each year?
Amphastar Pharmaceuticals, Inc. (:AMPH) has a recorded annual revenue of $644.40 M.
-
How much profit does Amphastar Pharmaceuticals, Inc. generate each year?
Amphastar Pharmaceuticals, Inc. (:AMPH) has a recorded net income of $644.40 M. Amphastar Pharmaceuticals, Inc. has generated $2.85 earnings per share over the last four quarters.
-
What is Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio?
Amphastar Pharmaceuticals, Inc. (:AMPH) has a price-to-earnings ratio of 15.02 and price/earnings-to-growth ratio is 2.
